Absci announced a $100M underwritten offering to support the advancement of ABS-201™, its AI-designed anti-PRLR antibody program, targeting androgenetic alopecia and endometriosis, while expanding its leadership in prolactin biology.
Absci Announces Pricing of $100M Underwritten Offering with Leading Strategic and Financial Investors
Share: